REG - Cambridge Cognition - Expanded partnership with Actinogen

Cambridge Cognition HoldingsAnnouncement

16/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250116:nRSP5116Ta&default-theme=true

RNS Number : 5116T  Cambridge Cognition Holdings PLC  16 January 2025

 

16 January 2025

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Actinogen Enhances Phase 2b/3 Alzheimer's Trial with Cambridge Cognition's
Full Digital Suite

 

Cambridge Cognition Holdings plc (AIM: COG), a brain health software group
specialising in digital products that advance brain health research and
treatment, is pleased to announce the expansion of its partnership with
Actinogen Medical Limited (ASX: ACW) for the Phase 2b/3 XanaMIA Alzheimer's
disease trial. Building on the successful integration of Cambridge Cognition's
full product suite including Cognitive Assessments (CANTAB), electronic
Clinical Outcome Assessments (eCOA), and automated quality assurance (AQUA)
during the first phase of this international study launched last year,
Actinogen will continue to leverage the company's validated tools for more
precise clinical measurements. This expanded collaboration underscores the
proven effectiveness of Cambridge Cognition's solutions, with Actinogen opting
to extend and enhance their use in this critical Alzheimer's research.

 

With dementia currently affecting 47 million people worldwide - a number
projected to increase to 75 million by 2030(1) - Cambridge Cognition is proud
to partner with innovative companies such as Actinogen who are making
pioneering steps within Alzheimer's research by developing a novel therapy for
neurological diseases designed to control elevated levels of brain cortisol
and thus slow or halt disease progression.

 

The Phase 2b/3 trial includes 220 patients with mild or moderate dementia due
to Alzheimer's disease and elevated levels of the plasma biomarker, pTau181.
Patients will receive emestedastat (Xanamem(2)) 10 mg or placebo, once daily,
and the trial is intended to show emestedastat's ability to slow progression
of Alzheimer's disease by assessing a variety of endpoints over a 36-week
period of treatment. The primary endpoint of the trial is the CDR-SB (Clinical
Dementia Rating scale - Sum of Boxes) supported by Cambridge Cognition,
alongside the secondary cognitive endpoint including Cambridge Cognition's
CANTAB Attention and working memory battery as well as the automated quality
assurance solution - AQUA. Ongoing use of Cambridge Cognition's full product
suite within this trial ensures greater comparability and superior data
quality across Actinogen's clinical development programme.

 

Rob Baker, Joint Managing Director and Chief Operating Officer at Cambridge
Cognition, commented:

"We are proud to deepen our collaboration with Actinogen in their important
work in Alzheimer's research. This partnership highlights the value of our
integrated platform in advancing innovative studies. By leveraging our
comprehensive suite of solutions, sponsors can optimise their clinical
assessments while upholding exceptional data quality standards. Our approach
ensures consistent, reliable endpoint measurements across the entire trial,
ultimately strengthening the scientific validity of research outcomes."

 

 Dr Steven Gourlay, Actinogen's CEO and MD, commented:

"Actinogen's commitment to advancing Alzheimer's research demands robust and
reliable data collection. Cambridge Cognition's integrated platform -
combining CANTAB, eCOA, and AQUA - provides us with validated cognitive
assessments and high-quality endpoint measurements that are crucial for
evaluating the therapeutic benefits of emestedastat. This comprehensive
solution strengthens our confidence in the data integrity for our XanaMIA
trial."

 

 

 1  The epidemiology and impact of dementia: current state and future trends.
Geneva: World Health Organization; 2015, Document WHO/MSD/MER/15.3, available
at http://www.who.int/mental_health/neurology/dementia/dementia_thematicbrief_
(http://www.who.int/mental_health/neurology/dementia/dementia_thematicbrief_)
epidemiology.pdf (accessed 8 March 2017)

2 Xanamem is a registered trademark of Actinogen Medical Limited

 

 

Enquiries:

 

 Cambridge Cognition Holdings plc                                 Tel: 012 2381 0700

 Rob Baker, Chief Operating Officer and Joint Managing Director

 Panmure Liberum Limited (NOMAD and Joint Broker)                 Tel: 020 7886 2968

 Will Goode / Freddy Crossley / Mark Rogers                       (Corporate Finance)

 Rupert Dearden                                                   (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                           Tel: 020 3903 7715

 David Poutney / James Serjeant
 Hudson Sandler (Financial PR and IR)                             Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus / Harry Griffiths                 cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a brain health software group specializing in digital
health products that advance brain health research and treatment.

 

The company offers four core products: CANTAB® assessments-providing
scientifically validated, highly sensitive, precise, and objective measures of
cognitive function correlated to neural networks; a flexible and proven eCOA
platform with an extensive library of instruments, enabling efficient study
setup and scalable data capture; rater training services that standardise
assessment delivery and scoring across clinical trials  and quality assurance
tools that ensure data integrity by automatically detecting deviations in
administration and scoring, saving time and money. These products collectively
improve clinical trial outcomes, enable early patient identification, and
enhance global efficiency in healthcare and pharmaceuticals.

 

For further information, visit: www.cambridgecognition.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.cambridgecognition.com%2F&data=05%7C02%7Chgriffiths%40hudsonsandler.com%7Cc696c6a3150d40f91a9508dcfdd13b58%7Ca33bdb157e25438ab1fd5c523a8866f9%7C0%7C0%7C638664322305026349%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=vQVOIVxNQ8WYYOufDnSVKUH0oa7PLvXjnP0VT%2FzCfJc%3D&reserved=0)

 

About Actinogen

 

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a
novel therapy for neurological and neuropsychiatric diseases associated with
dysregulated brain cortisol. There is a strong association between cortisol
and detrimental changes in the brain, affecting cognitive function, harm to
brain cells and long-term cognitive health. Cognitive function means how a
person understands, remembers and thinks clearly. Cognitive functions include
memory, attention, reasoning, awareness and decision-making. Actinogen is
currently developing its lead compound, emestedastat (Xanamem), as a promising
new therapy for Alzheimer's disease and depression and hopes to study Fragile
X syndrome and other neurological and psychiatric diseases in the future.
Reducing cortisol inside brain cells could have a positive impact in these and
many other diseases. The cognitive dysfunction, behavioural abnormalities, and
neuropsychological burden associated with these conditions is debilitating for
patients, and there is a substantial unmet medical need for new and improved
treatments.

 

For further information, visit: www.actinogen.com.au
(http://www.actinogen.com.au)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTDXGDBIBBDGUU